OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 181 - 190 of 742 studies

Oral and Gastrointestinal

GONDOMAR: Goals, Needs and outcome Determinants Of Multimodal therapy in Perianal Crohn's fistula - A multicentre cohort study (GONDOMAR)

Perianal fistula in Crohn's Disease (CD-pAF) is an abnormal tunnel that develops between the end of the bowel and the skin near the anus. It affects one third of Crohn's Disease (CD) patients causing significant morbidity and poor quality of life. Patients with CD-pAF are treated with several combined approaches involving medical and various surgical techniques with high failure rates (around 50%). The study will provide an evidence base to identify predictors of fistula healing, potentially modifiable factors, ...

GO TO STUDY Go

Oral and Gastrointestinal

Optimisation before Crohn's surgery using Exclusive Enteral Nutrition (OCEaN)

Crohn’s disease is a lifelong inflammatory illness that causes people to have severe stomach pains, chronic diarrhoea, and suffer weight loss. There is no cure. Crohn’s disease causes inflammation, ulceration, bleeding and narrowing of the digestive system. People can have periods of good health (“remission”) and times when symptoms are more active (“flare ups” or “relapses”). Medications can help keep it in remission, however one third of people will need surgery to remove/repair part of their diseased gut at some ...

GO TO STUDY Go

Inflammatory and immune system

Pain Phenotypes and their Underlying Mechanisms in Inflammatory Arthritis (PUMIA)

Controlling persistent pain is a significant unmet need for people living with Inflammatory arthritis (IA). There is emerging evidence that patients with IA exhibit different types of pain and central sensitisation contributes significantly to chronic pain. The treatment for different pain types will differ. One way in which we might rapidly improve the treatment of pain in IA is by identifying an individual’s pain type in the clinic, then tailor their pain treatment accordingly. Currently this is not routine practice and ...

GO TO STUDY Go

Cancer and neoplasms

Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial (SAFIR ABC-10)

Biliary tract cancers (BTC) are a heterogenous group of malignancies of the bile ducts and gallbladder. The incidence of BTC,especially cholangiocarcinoma (CCA),has risen steadily over the past 30 years. BTCs are common worldwide and are the fifth most common cancer in the developing world. Surgery is currently the only curative treatment but only 1 in 5 cases can be surgically removed and the proportion of patients who survive after 5 years from being diagnosed remains poor. Recently,it was demonstrated that roughly ...

GO TO STUDY Go

Cancer and neoplasms

Volatile Organic Compounds as Breath BIomarkers in Squamous Oesophageal Neoplasms (ViSON) (VISON)

Oesophageal squamous cell cancer (OSCC) is a cancer that grows in the food pipe and affects up to 2,000 people in the UK every year. Most patients are diagnosed when the cancer has spread to other body parts (advanced stage). As a result, the five-year survival is less than 20%. In comparison, when diagnosed early, nearly three out of four patients survive more than five years, indicating that early diagnosis improves survival. There are numerous challenges in detecting OSCC early. ...

GO TO STUDY Go

Infection

A dose finding human experimental infection study with SARS-CoV-2 Omicron BA.5 subvariant in healthy volunteers immunologically experienced against SARS-CoV-2 (COV-CHIM02)

The purpose of this study is to evaluate the safety and human clinical response to SARS-CoV-2 challenge with the omicron variant virus, in previously SARS-CoV-2 vaccinated people. We aim to establish the optimal challenge dose that causes re-infection and identify the lowest level of infectious dose necessary to produce viral replication in the upper respiratory tract of research volunteers while minimising risk of disease progression. Investigators aim to achieve an infection model which results in no symptoms, or symptoms no ...

GO TO STUDY Go

Cancer and neoplasms

Phase I, open-label, dose finding, safety, tolerability and exploratory study of THEO-260 in patients with high grade serous or endometrioid ovarian cancer (OCTOPOD)

This is a multi-centre, open label, FIH, multi-part trial to assess safety, tolerability, and preliminary efficacy of THEO-260 in patients with high grade serous or endometrioid ovarian cancer. The trial consists of 4 parts: Part A, Part B, Part C (optional) and Part D (optional). Part A (Dose Escalation/Finding Part): The trial part will use a model-assisted methodology for dose finding, Bayesian Optimal Interval (BOIN). Four (4) escalating dose levels are planned. In Part A, RP2D will be identified. Up to 18 ...

GO TO STUDY Go

Injuries and accidents

INITIATE: INCREASED MOBILITY IN HOSPITAL AFTER HIP FRACTURE (INITIATE)

Each year there are 70,000 new hip fractures in the UK, with an ongoing annual cost to health and social care services of £3 billion. After this injury, mobility and independence are so badly affected that one in six people never return home. This downward spiral of immobility and dependence contributes to a quarter of people dying within one year of the injury. National mobility targets have been set for hospitals. Firstly patients should be helped out of bed within 48 ...

GO TO STUDY Go

Blood

Graduated Compression stocking as an adjunct to Extended duration pharmacological thromboprophylaxis for venous thromboembolism prevention (GRACE)

Hospital-acquired thrombosis (HAT) is defined as any VTE within 90 days of hospital admission, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). HAT represents a significant cause of preventable death, with over 12,000 people dying each year from hospital-associated VTE in the UK. Previous studies report that the risk of untreated high-risk surgical patients developing HAT is as high as 40-60% in orthopaedic patients and 15-40% in general surgery patients. For these patients at highest risk of VTE, key ...

GO TO STUDY Go

Cancer and neoplasms

Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET)

In 2016, 11,563 women died from breast cancer in the UK. Most would have been prescribed hormone therapy (HT); sometimes known as endocrine therapy, which blocks the effect of oestrogen on breast cancer cells. HT is prescribed as a daily tablet, usually for at least five years and often up to 10 years. When women stop taking HT prematurely, or don’t take it as prescribed (known as “poor adherence”), they have up to a three times higher chance of the ...

GO TO STUDY Go